Correlations of JAK2–V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders

✍ Scribed by Matthaios Speletas; Eirini Katodritou; Chrisoula Daiou; Eudokia Mandala; Emmanouil Papadakis; Anna Kioumi; Konstantinos Ritis; Ioannis Korantzis

• Publisher: Elsevier Science
• Year: 2007
• Tongue: English
• Weight: 212 KB
• Volume: 31
• Category: Article
• ISSN: 0145-2126
• DOI: 10.1016/j.leukres.2006.09.005

✦ Synopsis

Recently, the acquired mutation JAK2-V617F has been described in the majority of patients with myeloproliferative disorders (MPDs). In this study we evaluated its clinical and laboratory correlates in 166 patients with MPDs. The mutation was detected by allele-specific PCR in 119 patients: 81.4% (35/43) of those with polycythemia vera, 69.1% (77/111) of those with essential thrombocythemia and 58.1% (7/12) of those with idiopathic myelofibrosis. The patients carrying the mutation were older (p=0.02) and displayed higher levels of Ht (p<0.01) and Hb (<0.01) and lower erythropoietin levels (p<0.01). Moreover, mutation-positive patients displayed a higher probability of having leucocytosis, splenomegaly and thrombotic events (three-fold, two-fold and two-fold, respectively) than mutation-negative patients. These correlations imply that the JAK2-V617F mutation may be useful for the classification and the management of patients with MPDs.